Ret Antibody (8D10C9): sc-101422
- Ret Antibody (8D10C9) is a mouse monoclonal IgG1 κ, cited in 2 publications, provided at 200 µg/ml
- raised against a recombinant protein corresponding to amino acids 896-1063 of Ret of human origin
- recommended for detection of Ret of human origin by WB, IP, IF, IHC(P) and ELISA
- See Ret (C-3): sc-365943 for Ret antibody conjugates, including AC, HRP, FITC, PE, Alexa Fluor® 488, 594, 647, 680 and 790.
- m-IgG Fc BP-HRP and m-IgG1 BP-HRP are the preferred secondary detection reagents for Ret Antibody (8D10C9) for WB and IHC(P) applications. These reagents are now offered in bundles with Ret Antibody (8D10C9) (see ordering information below).
QUICK LINKS
SEE ALSO...
Ret Antibody (8D10C9) is a mouse monoclonal IgG1 antibody that detects Ret in human samples through various applications including western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), immunohistochemistry with paraffin-embedded sections (IHCP), and enzyme-linked immunosorbent assay (ELISA). Ret is a crucial proto-oncogene that encodes a receptor tyrosine kinase involved in the signaling pathways of glial cell line-derived neurotrophic factor (GDNF), which plays a significant role in the development and maintenance of the nervous system. Ret (8D10C9) antibody recognizes the protein primarily located on the cell membrane, where Ret functions as a receptor that, upon binding to its ligand, activates downstream signaling cascades essential for neuronal survival and differentiation. This localization enables Ret to mediate critical cellular responses to external signals, influencing processes such as cell growth and survival. Notably, aberrations in the Ret gene, including tumor-specific rearrangements, have been implicated in various cancers, particularly papillary thyroid carcinoma, where these changes lead to the production of constitutively active fusion proteins that disrupt normal signaling pathways. Anti-Ret antibody (8D10C9) serves as an invaluable tool for researchers studying Ret in both normal physiology and disease states, providing insights into Ret function and potential as a therapeutic target.
Alexa Fluor® is a trademark of Molecular Probes Inc., OR., USA
LI-COR® and Odyssey® are registered trademarks of LI-COR Biosciences
Ret Antibody (8D10C9) References:
- RET, ROS1 and ALK fusions in lung cancer. | Takeuchi, K., et al. 2012. Nat Med. 18: 378-81. PMID: 22327623
- Towards precision oncology in RET-aberrant cancers. | Subbiah, V. and Roszik, J. 2017. Cell Cycle. 16: 813-814. PMID: 28318386
- Selective RET kinase inhibition for patients with RET-altered cancers. | Subbiah, V., et al. 2018. Ann Oncol. 29: 1869-1876. PMID: 29912274
- Advances in Targeting RET-Dependent Cancers. | Subbiah, V. and Cote, GJ. 2020. Cancer Discov. 10: 498-505. PMID: 32094155
- Efficacy of Selpercatinib in RET-Altered Thyroid Cancers. | Wirth, LJ., et al. 2020. N Engl J Med. 383: 825-835. PMID: 32846061
- Selpercatinib Aimed at RET-Altered Cancers. | Kurzrock, R. 2020. N Engl J Med. 383: 868-869. PMID: 32846067
- Precision oncology with selective RET inhibitor selpercatinib in RET-rearranged cancers. | Gouda, MA. and Subbiah, V. 2023. Ther Adv Med Oncol. 15: 17588359231177015. PMID: 37360768
- Strategies for mitigating adverse events related to selective RET inhibitors in patients with RET-altered cancers. | Nardo, M., et al. 2023. Cell Rep Med. 4: 101332. PMID: 38118420
- Targeting RET mutation in medullary thyroid cancer. | Assi, T., et al. 2024. Pharmacogenomics. 25: 113-115. PMID: 38450459
- RET Inhibitors in RET Fusion-Positive Lung Cancers: Past, Present, and Future. | Chen, MF., et al. 2024. Drugs. 84: 1035-1053. PMID: 38997570
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Ret Antibody (8D10C9) | sc-101422 | 200 µg/ml | $322.00 | |||
Ret Antibody (8D10C9): m-IgG Fc BP-HRP Bundle | sc-539760 | 200 µg Ab; 10 µg BP | $361.00 | |||
Ret Antibody (8D10C9): m-IgG1 BP-HRP Bundle | sc-541690 | 200 µg Ab; 20 µg BP | $361.00 |